Gerry Boushelle, associate director of global supply chain clinical-supply manufacturing in Pfizer’s (New York) global research and development division, presented a case study of the company’s implementation plan, conducted during 2006, at the 2007 Pharamaceutical Technology annual conference.
A US delegation of health officials is visiting China this week on a fact-finding mission regarding food and drug safety.
Speakers introduced laser-induced breakdown spectroscopy, an analytical technique largely unfamiliar to the pharmaceutical industry, to attendees at this year’s Pharmaceutical Technology annual conference.
During a July 10 meeting in Lisbon, the European Medicines Agency and Heads of Medicines Agencies reviewed the achievements of the European Risk Management Strategy during 2005–2007 and the program objectives for the next two years.
Feedback is urged on USP's proposed revisions to the General Notices.
By vetoing stem cell research funding, the President is vetoing potentially life-saving treatments.
Did you know that only one-third of prescribed pediatric drugs have been studied or labeled for pediatric use? The Best Pharmaceuticals for Children Act (BPCA) was enacted in 2002 to improve this statistic by providing companies with six months of additional marketing exclusivity if they conduct pediatric trials. The Government Accountability Office recently issued a report that examined data from studies conducted between 2002 and 2005 for drugs specified by the US Food and Drug Administration under BPCA.
Production sometimes follows the law of supply and reprimand.
Washington, DC (June 25)-More than five million US adults import prescription drugs from other countries, two million of them without an official prescription, according to a survey conducted by the Pharmaceutical Research and Manufacturers of America (PhRMA). Concerned about the number of counterfeit drugs entering the US, PhRMA launched the survey to determine who was importing prescription drugs and why.
USP is revising key documents to make them easier to use.
The financial performance of the pharmaceutical majors was generally favorable through the first half of 2007, with most companies reporting moderate to double-digit growth. Industry leader Pfizer, however, reported a sales decline for the second quarter and flat revenues through the first half of 2007. Pfizer Chairman and CEO Jeffrey Kindler says the company remains committed to its plans for cost-cutting, more outsourcing, and increasing its position in biologics.
The company begins production at a new $100-million manufacturing facility for prefilled injection systems, plans further investment in packaging facilities, and targets both early-phase development and commercial manufacture.
A roundup of manufacturing and service expansions.
The latest pacts from the pharmaceutical supply chain.
A roundup of company moves and positioning from the pharmaceutical and biotechnology industries and contract service providers.
The latest on active pharmaceutical ingredients in development and under commercial manufacture
People on the move
Moheb Nasr, director of the Office of New Drug Quality Assessment in the Center for Drug Evaluation and Research at the US Food and Drug Administration, addressed the agency’s history and progress in moving to a science- and risk-based approach in regulation at the Pharmaceutical Technology Annual Conference.
The US Food and Drug Administration opened for public comment its Draft Guidance for Industry, ?Cooperative Manufacturing Arrangements for Licensed Biologics.?
Rapid microbial testing in biopharmaceutical manufacturing is an important tool in potentially reducing process risk and manufacturing costs due to loss of production material. Amy McDaniel, associate director of the QC Microbial Science and Technology Department with Wyeth Biotech, discussed the company’s evaluation and implementation of rapid microbial testing at Wyeth’s facility in Andover, Massachusetts, at the Pharmaceutical Technology Annual Conference.
Adopting Lean Six Sigma practices in manufacturing and clinical development can help pharmaceutical companies cut costs and bring products to market faster, according to Carmen Medina, principal of Tunnell Consulting.
The US Food and Drug Administration’s Nanotechnology Task Force is urging the agency to develop a guidance and take steps toward addressing nanotechnology-based drugs and medical devices.
Merck & Co. acquires NovaCardia, Sanofi Pasteur completes vaccine-manufacturing facility, more
The IBM Corporation signed a $1.4-billion global outsourcing deal with AstraZeneca PLC (London). The seven-year agreement, which renews and expands on a current contract, covers the provision of IT infrastructure services to 60 countries and additional functions within AstraZeneca.
Xcellerex, Inc. received two Phase-I contracts from the Defense Advanced Research Projects Agency (Arlington, VA) for the Accelerated Manufacture of Pharmaceuticals program.
The US Food and Drug Administration announced the International Conference on Harmonization draft guidance Q10 Pharmaceutical Quality System in the Federal Register (Docket 2007D-0266, CDER 200783).
Beijing Med-Pharm acquires stake in Sunstone, JHP Pharmaceuticals buys King Pharmaceuticals facility, more
Although North America accounts for the largest share of the pharmaceutical market, Brazil, China, India, Indonesia, Mexico, Russia, and Turkey are projected to account for almost one-fifth of the global market by 2020. The rising participation in select countries' drug-development activities is evident by recent investment and outsourcing by the pharmaceutical majors.
Ventana Medical Systems, Inc.'s board of directors unanimously decided that Roche's (Basel, Switzerland) $75 per share cash offer is inadequate in multiple respects and contrary to the best interests of Ventana's stockholders.
The Bosch Group acquires Pharmatech, InterMune enters a supply agreement with Boehringer-Ingelheim, more.
